Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

Core Viewpoint - Phio Pharmaceuticals is participating in the Sidoti Micro-Cap Virtual Investor Conference to present updates on its INTASYL® gene silencing technology and ongoing clinical trials for skin cancer treatment [1][3]. Company Overview - Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® technology aimed at eliminating cancer [1][5]. - The company's lead clinical program involves the INTASYL compound PH-762, which targets the PD-1 gene associated with various skin cancers [5][6]. Clinical Trials - The ongoing Phase 1b clinical trial (NCT 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma, positioning it as a potential non-surgical treatment option for skin cancers [6]. Conference Details - The presentation by CEO Robert Bitterman is scheduled for May 22, 2025, at 10 AM ET, with one-on-one meetings with investors taking place on May 21-22, 2025 [2][3]. - Registration for the conference and meetings is free and open to all stakeholders and investors [2][3]. Sidoti Events Overview - Sidoti & Company, LLC has established Sidoti Events, LLC to enhance its conference business, focusing on small and microcap companies with market caps ranging from $200 million to $5 billion [4]. - Sidoti Events hosts eight investor conferences annually, providing corporate access and facilitating interactions between small and microcap issuers and investors [4].